| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Stonepine Capital Management, LLC | 10%+ Owner | 2900 NW CLEARWATER DRIVE, SUITE 100-11, BEND | /s/ Jon M. Plexico, Managing Mermber of Stonepine Capital Management, LLC | 02 Feb 2026 | 0001440771 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | QNRX | Ordinary Shares | 3,271,100 | 29 Jan 2026 | See Note | F1, F2 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | QNRX | Pre-Funded Warrants | 29 Jan 2026 | ADS | 81,212 | $0.000100 | See Note 2 | F3, F4 | ||||||
| holding | QNRX | Series H Warrants | 29 Jan 2026 | ADS | 121,212 | $9.08 | See Note 2 | F4, F5 | ||||||
| holding | QNRX | Series I Warrants | 29 Jan 2026 | ADS | 121,212 | $10.31 | See Note 2 | F4, F6 | ||||||
| holding | QNRX | Series J Warrants | 29 Jan 2026 | ADS | 121,212 | $12.38 | See Note 2 | F4, F7 | ||||||
| holding | QNRX | Series K Warrants | 29 Jan 2026 | ADS | 121,212 | $12.38 | See Note 2 | F4, F8 |
| Id | Content |
|---|---|
| F1 | These Ordinary Shares are held through 93,460 American Depositary Shares ("ADS") of the Issuer. Each ADS represents 35 Ordinary Shares. |
| F2 | The reporting persons are Stonepine Capital Management, LLC ("Stonepine"), Stonepine Capital, L.P. (the "Partnership"), Stonepine GP, LLC ("Stonepine GP") and Jon M. Plexico. Stonepine and Stonepine GP are the investment adviser and general partner, respectively, of the Partnership. Mr. Plexico is the control person of Stonepine and Stonepine GP. The Partnership hold these securities directly for the benefit of its investors. Stonepine and Stonepine GP may be deemed to indirectly beneficially own them as the investment adviser and general partner of the Partnership. Mr. Plexico may be deemed to indirectly beneficially own them as the control person of Stonepine and Stonepine GP. The filers disclaim beneficial ownership of the securities except to the extent of their respective pecuniary interests therein. |
| F3 | The pre-funded warrants are exercisable at any time and have no expiration date. |
| F4 | Each ADS represents 35 Ordinary Shares. |
| F5 | The Series H warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the Issuer's public announcement that the Issuer has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance. |
| F6 | The Series H warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the Issuer's public announcement that the Issuer has received Type C meeting minutes from the FDA indicating openness to baseline-controlled pivotal studies for QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance. |
| F7 | The Series J warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the public announcement of the receipt of either accelerated or traditional approval by the FDA of QRX003 for the treatment of Netherton Syndrome and (ii) five years from the date of issuance. |
| F8 | The Series K warrants are immediately exercisable and will expire on the earlier of (i) 30 days after the public announcement of the Issuer's sale of a Priority Review Voucher (PRV) and (ii) five years from the date of issuance. |
Stonepine is filing this Form 3 for itself, the Partnership, Stonepine GP and Mr. Plexico. The filers are filing this Form 3 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934.